Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL-140 + mFOLFOX-6 in 1st Line mCRC
NCT03426371Phase 3Terminated
- Sponsor
- Kelun-Biotech
- Start
- Mar 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by Kelun-Biotech. Started Mar 2018; status: terminated.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03426371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426371.